Exact Mass: 318.1726

Exact Mass Matches: 318.1726

Found 69 metabolites which its exact mass value is equals to given mass value 318.1726, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Eseramine

(3aS-cis)-3,3a,8,8a-Tetrahydro-N,3a,8-trimethyl-5-[[(methylamino)carbonyl]oxy]-pyrrolo[2,3-b]indole-1(2H)-carboxamide

C16H22N4O3 (318.1692)

Methylscopolamine

(1R,2R,4S,5S,7R)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium

C18H24NO4+ (318.1705)

Methylscopolamine is only found in individuals that have used or taken this drug. It is a muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. [PubChem]Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center). It does so by acting as a muscarinic antagonist.

Benzyl alcohol, 4-(2,4-diamino-5-pyrimidinylmethyl)-2,6-dimethoxy-alpha,alpha-dimethyl-

C16H22N4O3 (318.1692)

Robalzotan

3-(Dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboximidate

C18H23FN2O2 (318.1743)

D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4323; ORIGINAL_PRECURSOR_SCAN_NO 4321 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4808; ORIGINAL_PRECURSOR_SCAN_NO 4806 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX499; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4333; ORIGINAL_PRECURSOR_SCAN_NO 4329 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4786; ORIGINAL_PRECURSOR_SCAN_NO 4784 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4915; ORIGINAL_PRECURSOR_SCAN_NO 4913 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4810; ORIGINAL_PRECURSOR_SCAN_NO 4806 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9235; ORIGINAL_PRECURSOR_SCAN_NO 9230 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9194; ORIGINAL_PRECURSOR_SCAN_NO 9192 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9299; ORIGINAL_PRECURSOR_SCAN_NO 9298 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9319; ORIGINAL_PRECURSOR_SCAN_NO 9318 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9252; ORIGINAL_PRECURSOR_SCAN_NO 9248 INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX503; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; CONFIDENCE standard compound; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9252; ORIGINAL_PRECURSOR_SCAN_NO 9248 CONFIDENCE standard compound; INTERNAL_ID 1153; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9308; ORIGINAL_PRECURSOR_SCAN_NO 9306

4-(methoxymethyl)-2-methyl-3-[(2-methyl-1H-indol-4-yl)methyl]-1H-indole

C21H22N2O (318.1732)

(E)-9-(3,7-dimethylocta-2,6-dienyl)-3-methyl-1H-purine-2,6,8(3H,7H,9H)-trione

C16H22N4O3 (318.1692)

(1R,2E)-2-(6-hydroxyhexylidene)cyclopropyl-beta-D-glucopyranoside

C15H26O7 (318.1678)

Gly Arg Ser

C11H22N6O5 (318.1652)

Ser Arg Gly

C11H22N6O5 (318.1652)

Gly Ser Arg

C11H22N6O5 (318.1652)

Arg Ser Gly

C11H22N6O5 (318.1652)

Ser Gly Arg

C11H22N6O5 (318.1652)

Arg Gly Ser

C11H22N6O5 (318.1652)

LY 171883

1-[2-hydroxy-3-propyl-4-[4-(1H-tetrazol-5-yl)butoxy]phenyl]-ethanone

C16H22N4O3 (318.1692)

4-Hydroxypropranolol D7 hydrochloride

C16H15D7ClNO3 (318.1728)

3-Diazo-1,3-dihydro-1,1-diphenyl-2H-inden-2-one

C21H22N2O (318.1732)

1-(Triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid

C17H26N2O2Si (318.1763)

2-Methyl-2-propanyl 3-(7-hydroxypyrazolo[1,5-a]pyrimidin-5-yl)-1- piperidinecarboxylate

C16H22N4O3 (318.1692)

Morpholino(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)methanone

C16H23BN2O4 (318.1751)

TRIISOPROPYL CITRATE

C15H26O7 (318.1678)

Gly-leu-met-NH2

(2S)-2-[(2-aminoacetyl)amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpentanamide

C13H26N4O3S (318.1726)

[5-[(dimethylamino)methyl]-1-[(2-methylpropan-2-yl)oxycarbonyl]indol-2-yl]boronic acid

C16H23BN2O4 (318.1751)

4-Ethyl-2-fluoro-4-propyl-1,1:4,1-terphenyl

C23H23F (318.1784)

Tripropyl citrate

C15H26O7 (318.1678)

Morpholino(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)methanone

C16H23BN2O4 (318.1751)

Boc(L)-tryptophan hydrazide

C16H22N4O3 (318.1692)

4-[2-(4-Fluorophenyl)ethyl]-4-propyl-1,1-biphenyl

C23H23F (318.1784)

TERT-BUTYL 4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-YL)PIPERIDINE-1-CARBOXYLATE

C16H22N4O3 (318.1692)

Methscopolamine

C18H24NO4+ (318.1705)

A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03B - Belladonna and derivatives, plain > A03BB - Belladonna alkaloids, semisynthetic, quaternary ammonium compounds S - Sensory organs > S01 - Ophthalmologicals > S01F - Mydriatics and cycloplegics > S01FA - Anticholinergics C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics

Benzyl alcohol, 4-(2,4-diamino-5-pyrimidinylmethyl)-2,6-dimethoxy-alpha,alpha-dimethyl-

C16H22N4O3 (318.1692)

1-[(4-Phenyl-1-piperazinyl)methyl]-2-naphthalenol

C21H22N2O (318.1732)

Gly-Ser-Arg

C11H22N6O5 (318.1652)

L-Serine, L-arginylglycyl-

C11H22N6O5 (318.1652)

Octanedioic acid, bis(trimethylsilyl) ester

C14H30O4Si2 (318.1683)

Robalzotan

C18H23FN2O2 (318.1743)

C26170 - Protective Agent > C1509 - Neuroprotective Agent

L-N(omega)-Nitroarginine-2,4-L-diaminobutyric amide

C10H22N8O4 (318.1764)

ethyl (1R,2R,3S,5S)-3-benzoyloxy-8-methyl-8-azoniabicyclo[3.2.1]octane-2-carboxylate

C18H24NO4+ (318.1705)

Substituted Benzamide Derivative, 2

C21H22N2O (318.1732)

N-tert-butyl-1-hydroxy-5-nitro-4-spiro[benzimidazole-2,1-cyclohexane]imine

C16H22N4O3 (318.1692)

4-(4-propan-2-ylphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-one

C21H22N2O (318.1732)

N-butyl-1-hydroxy-5-nitro-4-spiro[benzimidazole-2,1-cyclohexane]imine

C16H22N4O3 (318.1692)

2,5-dimethyl-1-(3-methylphenyl)-N-(4-methylphenyl)-3-pyrrolecarboxamide

C21H22N2O (318.1732)

2,6-Dimethyl-4-(4-phenyl-2-quinolinyl)morpholine

C21H22N2O (318.1732)

(9,9-Dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl) (2R)-3-hydroxy-2-phenylpropanoate

C18H24NO4+ (318.1705)

Ser-Gly-Arg

C11H22N6O5 (318.1652)

Gly-Arg-Ser

C11H22N6O5 (318.1652)

(8R)-8-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxononanoic acid

C15H26O7 (318.1678)

9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-oxononanoic acid

C15H26O7 (318.1678)

Arg-Ser-Gly

C11H22N6O5 (318.1652)

Ser-Arg-Gly

C11H22N6O5 (318.1652)

6-Bromo-4-iodo-quinoline

C13H26N4O3S (318.1726)

[(1S,5S)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

C18H24NO4+ (318.1705)

Arg-Gly-Ser

C11H22N6O5 (318.1652)

SIRT2-IN-11

C21H22N2O (318.1732)

SIRT2-IN-11 (AEM1) is a selective SIRT2 inhibitor with an IC50 value of 18.5 μM. SIRT2-IN-11 p53-dependently induces apoptosis, activates expression of CDKN1A, PUMA and NOXA, and increases acetylation of p53. SIRT2-IN-11 can be used for the research of p53-related cancers[1].